Cargando…

Dornase alfa in Cystic Fibrosis: indications, comparative studies and effects on lung clearance index

Cystic fibrosis (CF) is the most common inherited disease in Caucasian populations, affecting around 50,000 patients in Europe and 30,000 in United States. A mutation in CF trans-membrane conductance regulator (CFTR) gene changes a protein (a regulated chloride channel), which is expressed in many t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terlizzi, Vito, Castellani, Chiara, Taccetti, Giovanni, Ferrari, Beatrice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351191/ https://www.ncbi.nlm.nih.gov/pubmed/35927765 http://dx.doi.org/10.1186/s13052-022-01331-5

Ejemplares similares

Effect of Dornase Alfa on the Lung Clearance Index in Children with Cystic Fibrosis: A Lesson from a Case Series
por: Terlizzi, Vito, et al.
Publicado: (2022)

Dornase alpha use in patients with cystic fibrosis
por: Marostica, Paulo José C.
Publicado: (2013)

Modulator Therapy in Cystic Fibrosis Patients with cis Variants in F508del Complex Allele: A Short-Term Observational Case Series
por: Terlizzi, Vito, et al.
Publicado: (2022)

A first-year dornase alfa treatment impact on clinical parameters of patients with cystic fibrosis: the Brazilian cystic fibrosis multicenter study
por: Rozov, Tatiana, et al.
Publicado: (2013)

The use of dornase alfa in patients with COVID-19
por: Ramachandram, Dinesh Sangarran, et al.
Publicado: (2023)

Hypertonic saline in people with cystic fibrosis: review of comparative studies and clinical practice
por: Terlizzi, Vito, et al.
Publicado: (2021)

Aerosol Delivery of Dornase Alfa Generated by Jet and Mesh Nebulizers
por: Chang, Kyung Hwa, et al.
Publicado: (2020)

G378X‐I148T CFTR variant: A new complex allele in a cystic fibrosis newborn with pancreatic insufficiency
por: Terlizzi, Vito, et al.
Publicado: (2022)

Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome
por: Earhart, A.P., et al.
Publicado: (2020)

The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome
por: Toma, Andrew, et al.
Publicado: (2021)

Early Effects of Elexacaftor-Tezacaftor-Ivacaftor Therapy on Magnetic Resonance Imaging in Patients with Cystic Fibrosis and Advanced Lung Disease
por: Macconi, Letizia, et al.
Publicado: (2022)

Comparison between Gibson–Cooke and Macroduct Methods in the Cystic Fibrosis Neonatal Screening Program and in Subjects Who Are Cystic Fibrosis Screen-Positive with an Inconclusive Diagnosis
por: Dolce, Daniela, et al.
Publicado: (2023)

Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype
por: Terlizzi, Vito, et al.
Publicado: (2021)

Preliminary report of in vitro and in vivo effectiveness of dornase alfa on SARS-CoV-2 infection
por: Okur, H.K., et al.
Publicado: (2020)

Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19
por: Holliday, Zachary M., et al.
Publicado: (2021)

Concomitant Use of Elexacaftor/Tezacaftor/Ivacaftor and Etanercept in a Cystic Fibrosis Patient with Juvenile Idiopathic Arthritis
por: Orsini, Sara Immacolata, et al.
Publicado: (2023)

Lung clearance index in subjects with cystic fibrosis in Italy
por: Lombardi, Enrico, et al.
Publicado: (2019)

Use of dornase alfa in the paediatric intensive care unit: current literature and a national cross-sectional survey
por: den Hollander, Bibiche, et al.
Publicado: (2022)

Clinical characteristics and outcome of SARS –CoV-2 infection in patients with cystic fibrosis managed at home
por: Terlizzi, V., et al.
Publicado: (2022)

Lung clearance index in adults with non-cystic fibrosis bronchiectasis
por: Gonem, Sherif, et al.
Publicado: (2014)

Applications of lung clearance index in monitoring children with cystic fibrosis
por: Fretzayas, Andrew, et al.
Publicado: (2019)

Cystic fibrosis in Tuscany: evolution of newborn screening strategies over time to the present
por: Botti, Matteo, et al.
Publicado: (2021)

Auxological and Endocrinological Features in Children and Adolescents with Cystic Fibrosis
por: Ferrari, Vittorio, et al.
Publicado: (2022)

Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series
por: Weber, Andrew G., et al.
Publicado: (2020)

Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: A case series
por: Weber, Andrew G., et al.
Publicado: (2020)

Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype
por: Comegna, Marika, et al.
Publicado: (2021)

Clinical and Genotypical Features of False-Negative Patients in 26 Years of Cystic Fibrosis Neonatal Screening in Tuscany, Italy
por: Taccetti, Giovanni, et al.
Publicado: (2020)

Lung Clearance Index in Children with Cystic Fibrosis during Pulmonary Exacerbation
por: Walicka-Serzysko, Katarzyna, et al.
Publicado: (2021)

Intrapleural Tissue Plasminogen Activator and Dornase Alfa Administration for a Multiloculated Recurrent Malignant Pleural Effusion: A Case Report
por: Nikoomanesh, Kia, et al.
Publicado: (2022)

A Multicentre Italian Study on the Psychological Impact of an Inconclusive Cystic Fibrosis Diagnosis after Positive Neonatal Screening
por: Tosco, Antonella, et al.
Publicado: (2023)

Lung clearance index to characterize clinical phenotypes of children and adolescents with cystic fibrosis
por: Gambazza, Simone, et al.
Publicado: (2022)

Extensive CFTR Gene Analysis Revealed a Higher Occurrence of Cystic Fibrosis Transmembrane Regulator-Related Disorders (CFTR-RD) among CF Carriers
por: Esposito, Maria Valeria, et al.
Publicado: (2020)

Longitudinal lung clearance index and association with structural lung damage in children with cystic fibrosis
por: Svedberg, Marcus, et al.
Publicado: (2023)

Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease
por: Terlizzi, Vito, et al.
Publicado: (2021)

Impact of Pancreatitis-Associated Protein on Newborn Screening Outcomes and Detection of CFTR-Related Metabolic Syndrome (CRMS)/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): A Monocentric Prospective Pilot Experience
por: Bianchimani, Chiara, et al.
Publicado: (2022)

P163 Effects of the SARS-CoV-2 pandemic on attendance at the cystic fibrosis centre and the definition of the microbiological status of cystic fibrosis patients in Tuscany
por: Dolce, D., et al.
Publicado: (2021)

Shortened Lung Clearance Index is a repeatable and sensitive test in children and adults with cystic fibrosis
por: Hannon, David, et al.
Publicado: (2014)

An observational study of the lung clearance index throughout childhood in cystic fibrosis: early years matter
por: Davies, Gwyneth, et al.
Publicado: (2020)

Longitudinal assessment of lung clearance index to monitor disease progression in children and adults with cystic fibrosis
por: Horsley, Alex R, et al.
Publicado: (2022)

Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study
por: Carnovale, Vincenzo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_okh7tfac527gv57mmi67isg6mb